Gene Suppression Panel for Chemosensitizing Cancer Cells

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current cancer treatments for solid tumors, such as lung cancer, lack effective molecular selection criteria and targeted therapies, particularly for chemoresistant and radioresistant cancers, where the Jak/Stat pathway plays a crucial role in tumor development and resistance.

Innovation Solution

A panel of genes associated with the Jak/Stat pathway, including DHX58, PLSCR1, USP18, PSMB10, IFITM1, OASL, EPSTL1, LGALS3BP, IFIH1, ABCC3, DTX3L, PSMB9, IRF9, TAGLN, IFIT2, TPD52L1, CXCL9, GBP1, BST2, SP110, HERC5, CCL2, WARS, and MCL1, are identified and targeted using inhibitors like siRNA, shRNA, or small molecules to suppress their expression, thereby sensitizing cancer cells to chemotherapy and radiotherapy.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If conventional chemotherapy and radiotherapy are used for solid tumors, then tumor treatment is provided, but chemoresistance and radioresistance develop reducing treatment effectiveness

Engineering Contradiction:

Improvetreatment effectivenessVSAvoidchemoresistance and radioresistance

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent applies preliminary action by suppressing Jak/Stat pathway genes (using siRNA, shRNA, or small molecule inhibitors) before administering chemotherapy or radiotherapy. This pre-treatment sensitizes cancer cells to subsequent therapy by downregulating resistance-related genes, thereby improving treatment effectiveness and overcoming chemoresistance and radioresistance

Inventive Principle:

Principle #10Preliminary action

Solution Approach 2:

The patent uses Jak/Stat pathway inhibitors as intermediary agents between the patient's immune system and the cancer cells. These inhibitors (siRNA, shRNA, or small molecules) mediate the suppression of target genes, creating a bridge that enhances the efficacy of conventional therapies by modulating the cancer cells' response to treatment

Inventive Principle:

Principle #24Intermediary (Mediator)

2Reliability

If Jak/Stat pathway inhibitors are used to sensitize cancer cells, then treatment sensitivity improves, but the complexity of the treatment protocol increases

Engineering Contradiction:

Improvetreatment sensitivityVSAvoidtreatment protocol complexity

Core Design Contradiction:

ReliabilityVSDevice complexity

Solution Approach 1:

The patent employs small molecule Jak/Stat pathway inhibitors that can function through multiple mechanisms simultaneously - they inhibit Jak kinases, block Stat activation, and downregulate downstream target genes. This multi-functionality allows a single agent to achieve gene suppression and sensitization effects, simplifying the overall treatment approach while maintaining improved treatment sensitivity

Inventive Principle:

Principle #6Universality (Multi-functionality)

Data Source

PatentUS9790504B2Anti-tumor therapy

Publication Date: 2017.10.17 UNIVERSITY OF CHICAGO

AI summary

Panels, compositions, and methods for treating cancer in a subject in need thereof are disclosed involving one or more genes the suppression of which renders the cancer chemosensitive and/or radiosensitive.